GO
Loading...

Europe Video

Jenny Dawson, founder of Rubies in the Rubble, and winner of the Veuve Cliquot new generation award, explains that her company is a luxury food brand that aims to raise awareness about global food imbalances.

Time to get back into EM?     Tue, 13 May '14 | 11:35 AM ET

Maarten-Jan Bakkum, global emerging markets strategist at ING Investment Management, says emerging markets have recovered a bit, due to "political excitement" and expectations of improved liquidity.

'Momentum trade' in European bonds     Tue, 13 May '14 | 11:20 AM ET

Didier Duret, global CIO of ABN Amro Private Banking, and Louis Gargour, CIO of LNG Capital, discuss how deflation fears have created a momentum trade in European government bonds.

European market closes higher     Tue, 13 May '14 | 11:30 AM ET

European bourses closed higher on Tuesday, as investors mulled whether new measures by the European Central Bank could soon be announced.

Pascal Soriot, AstraZeneca CEO, says the group has what it takes to succeed on its own and that its "stand-alone strategy" will create value for its shareholders.

AstraZeneca has the "critical mass" to succeed internationally, Pascal Soriot, CEO of AstraZeneca told CNBC, also discussing the group¿s pipeline.

Gerhard Roiss, CEO of OMV, discusses the impact of the Russian sanctions on European gas, and dismisses calls for a unified gas price across the region.

Scott Moeller, director of the M&A research centre at Cass Business School, discusses the potential AstraZeneca takeover and Pfizer's strategy.

Jason Kolbert, head of health care equity research at Maxim Group, says Pfizer's takeover bid is driven by AstraZeneca's pipeline, strategic tax advantages and cost savings.

Ian Read, CEO of Pfizer, says there is a "very strong industrial rationale" behind its AstraZeneca's takeover bid, as the groups' pipelines would both benefit from being combined.

Why you should favour large-caps     Tue, 13 May '14 | 5:30 AM ET

Andrew Burkly, head of institutional portfolio strategy at Oppenheimer & Co., says the underlying fundamentals for U.S. equities remain "pretty constructive", and large cap stocks should outperform small caps this year.

'Brand EU' not strong enough: Expert     Tue, 13 May '14 | 4:40 AM ET

Nicolas De Santis, president and secretary general at Gold Mercury International, says the European Union has an "identity problem" and needs a stronger brand and identity.

Christian Keller, head of emerging markets research at Barclays, says emerging market credit valuation is quite attractive but advises being "choosy and picky."

Robots and flatpacks: The future of construction

Chuka Umunna, U.K. shadow business secretary, says Labour is advocating the introduction of a new "public interest control" category to relate to U.K. science and R&D.

Chuka Umunna, U.K. shadow business secretary, says the potential AstraZeneca takeover by Pfizer should be looked at as of national economic interest, and that more should be done to protect R&D jobs.

Ranjith Gopinathan, program manager for life sciences and health care practice at Frost & Sullivan, explains why he believes the Pfizer/AstraZeneca deal would be positive.

Tony Burke, assistant general secretary of Unite, says Pfizer's promises to keep jobs in and research in the U.K. are "not worth the paper they are written on".

Paul Donovan, global economist at UBS, discusses the U.K.'s real estate market and whether the soaring house prices in London are sustainable.

Frederic Oudea, CEO of Société Générale, says the Ukraine crisis has led to a slowdown in the Russian economy, but the bank confirms its commitment to the country.

Howard Silverblatt, senior index analyst at S&P Dow Jones Indices, says U.S. corporates are being "stingy" with their dividend payouts despite sitting on large cash piles.

European shares continued their move higher on Tuesday following a strong finish on Wall Street Monday where the Dow Jones and S&P 500 both closed at record highs.

Katy Clark MP, a member of the U.K. parliament's business select committee, and Roger Barker, director of corporate governance at the Institute of Directors, discuss the concerns surrounding Pfizer's bid to take over AstraZeneca.

Carolyn McCall, CEO of easyJet, says that lawmakers should avoid "political football" over proposals to increase capacity at the U.K.'s airports.

Growing in core markets: easyJet CEO     Tue, 13 May '14 | 2:05 AM ET

Carolyn McCall, CEO of easyJet, says the company is growing in its core markets but is not expanding into completely new regions. McCall also defends the price structure at easyJet, saying that there are "no bolstering add-ons".

Federico Ghizzoni, CEO of Unicredit, says the Italian lender will get through the European Central Bank's stress tests without major problems, but it will be a "tough exercise" for the region's banking sector.

Rising sterling not worrying BoE: Pro     Tue, 13 May '14 | 1:20 AM ET

Nour Al Hammoury, market strategist at ADS Securities, says the current level of sterling is not worrying the Bank of England but a further rise could alarm the central bank.

Federico Ghizzoni, CEO of Unicredit, discusses the Italian bank's results and the lending trend in the company's markets.

Ron Kruszewski, chairman and CEO of Stifel Financial, comments on the group's acquisition of Oriel Securities and monetary policy in the U.S. and Europe.

Sterling is 'definitely vulnerable': Pro     Mon, 12 May '14 | 11:00 AM ET

Percival Stanion, head of asset allocation at Baring Asset Management, says the UK pound is "definitely vulnerable" as the outcome of the 2015 general elections may not be as business-friendly as investors may expect.

Contact Europe Video

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More